Seminars in Oncology
Volume 29, Issue 4 , Pages 400-409 , August 2002

Isolated limb perfusion in locally advanced cutaneous melanoma

References 

  1. Creech O, Krementz E, Ryan R. Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148:616–632
  2. Cavaliere R, Ciocatto EC, Giovanella BC, et al.  Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer. 1967;20:1351–1381
  3. Stehlin JS. Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg Gynecol Obstet. 1969;129:305–308
  4. Lienard D, Eggermont AM, Schraffordt Koops H, et al.  Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res. 1994;4(suppl 1):21–26
  5. Kroon BB. Regional isolation perfusion in melanoma of the limbs; accomplishments, unsolved problems, future. Eur J Surg Oncol. 1988;14:101–110
  6. Thompson JF, Kam PC, Waugh RC, et al.  Isolated limb infusion with cytotoxic agents: A simple alternative to isolated limb perfusion. Semin Surg Oncol. 1998;14:238–247
  7. Erttmann R, Erb N, Steinhoff A, et al.  Pharmacokinetics of doxorubicin in man: dose and schedule dependence. J Cancer Res Clin Oncol. 1988;114:509–513
  8. Briele HA, Djuric M, Jung DT, et al.  Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities. Cancer Res. 1985;45:1885–1889
  9. Fraker DL. Hyperthermic regional perfusion for melanoma and sarcoma of the limbs. Curr Probl Surg. 1999;36:841–907
  10. Wu ZY, Smithers BM, Roberts MS. Melphalan dosing regimens for management of recurrent melanoma by isolated limb perfusion: Application of a physiological pharmacokinetic model based on melphalan distribution in the isolated perfused rat hindlimb. Melanoma Res. 1997;7:252–264
  11. Sonneveld EJ, Vrouenraets BC, van Geel BN, et al.  Systemic toxicity after isolated limb perfusion with melphalan for melanoma. Eur J Surg Oncol. 1996;22:521–527
  12. Patt Y, Calvo D, Benjamin R. Treatment of regionally confined metastatic tumors with arterial infusion of cisplatin. In:  Prestokyo A,  Crooke S,  Carter S editor. Cisplatin Current Status and New Developments. New York, NY: Academic Press; 1980;p. 495–509
  13. Fletcher WS, Pommier RF, Woltering EA, et al.  Pharmacokinetics and results of dose escalation in cis-platin hyperthermic isolation limb perfusion. Ann Surg Oncol. 1994;1:236–243
  14. Guchelaar HJ, Hoekstra HJ, de Vries EG. Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremities. Br J Cancer. 1992;65:898–902
  15. Pommier RF, Moseley HS, Cohen J, et al.  Pharmacokinetics, toxicity, and short-term results of cisplatin hyperthermic isolated limb perfusion for soft-tissue sarcoma and melanoma of the extremities. Am J Surg. 1988;155:667–671
  16. Papa MZ, Klein E, Karni T, et al.  Regional hyperthermic perfusion with cisplatin following surgery for malignant melanoma of the extremities. Am J Surg. 1996;171:416–420
  17. Coit D, Bajorin D, Menedez-Botet C. A phase I trial of hyperthermic isolation limb perfusion (HILP) using cisplatin (CDDP) for metastatic melanoma. Proc Am Soc Clin Oncol. 1991;10:294; (abstr)
  18. Renard N, Lienard D, Lespagnard L. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha). Int J Cancer. 1994;57:656–663
  19. de Wilt JH, Manusama ER, van Tiel ST, et al.  Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer. 1999;80:161–166
  20. Feinberg B, Kurzrock R, Talpaz M, et al.  A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol. 1988;6:1328–1334
  21. Gutman M, Inbar M, Lev-Shlush D, et al.  High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer. 1997;79:1129–1137
  22. Pontes L, Lopes M, Ribeiro M, et al.  Isolated limb perfusion with fotemustine after chemosensitization with dacarbazine in melanoma. Melanoma Res. 1997;7:417–419
  23. Casara D, Rubello D, Pilati P. A simplified procedure for continuous intraoperative external monitoring of systemic leakage during isolated limb perfusion cancer therapy. Eur J Nucl Med. 2001;28:1174; (abstr)
  24. Hohenberger P, Haier J, Schlag PM. Rhabdomyolysis and renal function impairment after isolated limb perfusion—Comparison between the effects of perfusion with rhTNF alpha and a ‘triple-drug’ regimen. Eur J Cancer. 1997;33:596–601
  25. Koops HS, Vaglini M, Suciu S, et al.  Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593 J Clin Oncol. 1998;16:2906–2912
  26. Hafstrom L, Rudenstam CM, Blomquist E, et al.  Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group. J Clin Oncol. 1991;9:2091–2094
  27. Hochster H, Strawderman MH, Harris JE, et al.  Conventional dose melphalan is inactive in metastatic melanoma: Results of an Eastern Cooperative Oncology Group Study (E1687). Anticancer Drugs. 1999;10:245–248
  28. Klaase JM, Kroon BB, van Geel AN, et al.  Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery. 1994;115:39–45
  29. Klaase JM, Kroon BB, van Geel AN, et al.  Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. J Am Coll Surg. 1994;178:564–572
  30. Sutherland CM, Mather FJ, Krementz ET. Factors influencing the survival of patients with regional melanoma of the extremity treated by perfusion. Surg Gynecol Obstet. 1987;164:111–118
  31. Hoekstra HJ, Schraffordt Koops H, de Vries LG, et al.  Toxicity of hyperthermic isolated limb perfusion with cisplatin for recurrent melanoma of the lower extremity after previous perfusion treatment. Cancer. 1993;72:1224–1229
  32. Aigner K, Hild P, Henneking K. Regional perfusion with cisplatin and dacarbazine. Recent Results Cancer Rese. 1983;86:239–245
  33. Thompson JF, Gianoutsos MP. Isolated limb perfusion for melanoma: Effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg. 1992;16:227–233
  34. Vaglini M, Belli F, Marolda R, et al.  Hyperthermic antiblastic perfusion with DTIC in stage IIIA-IIIAB melanoma of the extremities. Eur J Surg Oncol. 1987;13:127–129
  35. Shiu MH, Knapper WH, Fortner JG, et al.  Regional isolated limb perfusion of melanoma intransit metastases using mechlorethamine (nitrogen mustard). J Clin Oncol. 1986;4:1819–1826
  36. Lienard D, Eggermont AM, Koops HS, et al.  Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: A multicentre randomized phase II study. Melanoma Res. 1999;9:491–502
  37. Mian R, Henderson MA, Speakman D, et al.  Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion. Can J Surg. 2001;44:189–192
  38. Lienard D, Eggermont AM, Kroon BB, et al.  Isolated limb perfusion in primary and recurrent melanoma: Indications and results. Semin Surg Oncol. 1998;14:202–209
  39. Barker WC, Andrich MP, Alexander HR, et al.  Continuous intraoperative external monitoring of perfusate leak using iodine-131 human serum albumin during isolated perfusion of the liver and limbs. Eur J Nucl Med. 1995;22:1242–1248
  40. Vargas H, McFarlane M, Vargas M. Effects of intravascular tumor necrosis factor on vascular permeability and blood flow in tumor and normal tissue. Proc Am Assoc Cancer Res. 1996;37:486; (abstr)
  41. Thom AK, Alexander HR, Andrich MP, et al.  Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan. J Clin Oncol. 1995;13:264–273
  42. Vrouenraets BC, Hart GA, Eggermont AM, et al.  Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J Am Coll Surg. 1999;188:522–530
  43. van Geel AN, van Wijk J, Wieberdink J. Functional morbidity after regional isolated perfusion of the limb for melanoma. Cancer. 1989;63:1092–1096
  44. Vrouenraets BC, Klaase JM, Kroon BB, et al.  Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Arch Surg. 1995;130:43–47
  45. Klaase JM, Kroon BB, van Geel BN, et al.  Patient- and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities. Am J Surg. 1994;167:618–620
  46. Bonifati DM, Ori C, Rossi CR, et al.  Neuromuscular damage after hyperthermic isolated limb perfusion in patients with melanoma or sarcoma treated with chemotherapeutic agents. Cancer Chemother Pharmacol. 2000;46:517–522
  47. Klicks RJ, Vrouenraets BC, Nieweg OE, et al.  Vascular complications of isolated limb perfusion. Eur J Surg Oncol. 1998;24:288–291
  48. Hahn GM. Metabolic aspects of the role of hyperthermia im mammalian cell inactivation and their possible relevance to cancer treatment. Cancer Res. 1974;34:3117–3123
  49. Dudar TE, Jain RK. Differential response of normal and tumor microcirculation to hyperthermia. Cancer Res. 1984;44:605–612
  50. Ohno S, Strebel FR, Stephens LC, et al.  Increased therapeutic efficacy induced by tumor necrosis factor alpha combined with platinum complexes and whole-body hyperthermia in rats. Cancer Res. 1992;52:4096–4101
  51. Miller RC, Richards M, Baird C, et al.  Interaction of hyperthermia and chemotherapy agents; cell lethality and oncogenic potential. Int J Hyperthermia. 1994;10:89–99
  52. Alexander H, Rosenberg SA. Tumor necrosis factor: Clinical applications. In:  De Vita V,  Hellman S,  Rosenberg S editor. Biologic Therapy of Cancer. Philadelphia, PA: Lippincott; 1991;p. 378–392
  53. Di Filippo F, Rossi CR, Vaglini M, et al.  Hyperthermic antiblastic perfusion with alpha tumor necrosis factor and doxorubicin for the treatment of soft tissue limb sarcoma in candidates for amputation: results of a phase I study. J Immunother. 1999;22:407–414
  54. Cavaliere R, Di Filippo F, Giannarelli D, et al.  Hyperthermic antiblastic perfusion in the treatment of local recurrence or “in-transit” metastases of limb melanoma. Semin Surg Oncol. 1992;8:374–380
  55. Lienard D, Ewalenko P, Delmotte JJ, et al.  High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 1992;10:52–60
  56. Vrouenraets BC, Eggermont AM, Hart AA, et al.  Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor-alpha versus toxicity after melphalan alone. Eur J Surg Oncol. 2001;27:390–395
  57. Lotze M, Dallal R, Kirkwood J, Flickinger J. Cuteneous melanoma. In: ed 6.  De Vita V,  Hellman S,  Rosenberg S editor. Cancer Principles and Practice of Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2001;p. 2012–2069
  58. van de Merwe SA, van den Berg AP, Kroon BB, et al.  Modification of human tumour and normal tissue pH during hyperthermic and normothermic antiblastic regional isolation perfusion for malignant melanoma: A pilot study. Int J Hyperthermia. 1993;9:205–217
  59. van Der Veen AH, ten Hagen TL, de Wilt JH, et al.  An overview on the use of TNF-alpha: Our experience with regional administration and developments towards new opportunities for systemic application. Anticancer Res. 2000;20:3467–3474
  60. Scanlon KJ, Ohta Y, Ishida H, et al.  Oligonucleotide-mediated modulation of mammalian gene expression. FASEB J. 1995;9:1288–1296
  61. Dean N, McKay R, Miraglia L, et al.  Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression. Cancer Res. 1996;56:3499–3507
  62. Eggermont AM, ten Hagen TL. Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: Credits, debits, and future perspectives. Curr Oncol Rep. 2001;3:359–367
  63. Bulman AS, Jamieson CW. Isolated limb perfusion with melphalan in the treatment of malignant melanoma. Br J Surg. 1980;67:660–662
  64. Kroon BB, Van Geel AN, Benckhuijsen C, et al.  Normothermic isolation perfusion with melphalan for advanced melanoma of the limbs. Anticancer Res. 1987;7:441–442
  65. Kroon BB, Klaase JM, van Geel BN, et al.  Results of a double perfusion schedule with melphalan in patients with melanoma of the lower limb. Eur J Cancer. 1993;3:325–328
  66. Di Filippo F, Calabro A, Giannarelli D, et al.  Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer. 1989;63:2551–2561
  67. Storm FK, Morton DL. Value of therapeutic hyperthermic limb perfusion in advanced recurrent melanoma of the lower extremity. Am J Surg. 1985;150:32–35
  68. Jonsson P, Hafstrom L, Hugander A. Results of regional hyperthermic perfusion for primary and recurrent melanomas of the extremities. Recent Results Cancer Res. 1983;86:277–282
  69. Lejeune F, Deloof T, Ewalenko P. Objective regression of unexcised melanoma in transit metastases after hyperthermic isolation perfusion of the limbswith melphalan. Recent Results Cancer Res. 1983;86:268–276
  70. Skene AI, Bulman AS, Williams TR, et al.  Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb. Br J Surg. 1990;77:765–767
  71. Rossi CR, Foletto M, Vecchiato A, et al.  Management of cutaneous melanoma M0: State of the art and trends. Eur J Cancer. 1997;33:2302–2312
  72. Krementz ET, Ryan RF. Chemotherapy of melanoma of the extremities of perfusion: Fourteen years clinical experience. Ann Surg. 1972;175:900–917
  73. Scott R, Blackie R, Kerr D. Melphalan in isolated limb perfusion for malignant melanoma, bolus or divided dose, tissue levels, the pH effect. In:  Jakesz R,  Rainer H editor. Progress in Regional Cancer Treatment. Berlin, Germany,: Springer Verlag; 1990;p. 195–200
  74. Benckhuijsen C, Kroon BB, van Geel AN, et al.  Regional perfusion treatment with melphalan for melanoma in a limb: An evaluation of drug kinetics. Eur J Surg Oncol. 1988;14:157–163
  75. Lejeune FJ, Ghanem GE. A simple and accurate new method for cytostatics dosimetry in isolation perfusion of the limbs based on exchangeable blood volume determination. Cancer Res. 1987;47:639–643
  76. Briele HA, Djuric M, Jung DT, et al.  Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities. Cancer Res. 1985;45:1885–1889
  77. Lienard D, Lejeune FJ, Ewalenko P. In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion. World J Surg. 1992;16:234–240
  78. Vaglini M, Belli F, Ammatuna M, et al.  Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon, and melphalan. Cancer. 1994;73:483–492
  79. Fraker DL, Alexander HR, Andrich M, et al.  Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: Results of a tumor necrosis factor dose-escalation study. J Clin Oncol. 1996;14:479–489
  80. Fraker D, Alexander H, Bartlett D, et al.  A prospective randomized trial of therapeutic isolated limb perfusion comparing melphalan versus melphalan, tumor necrosis factor and interferon-an initial report. Proc Soc Surg Oncol. 1996;49:6; (abstr)
  81. Wieberdink J, Benckhuijsen C, Braat RP, et al.  Dosimetry in isolated perfusion of the limb by assessment of perfused volume and grading of toxic reaction. Eur J Cancer Clin Oncol. 1982;18:905

☆ Address reprint requests to Carlo Riccardo Rossi, MD, University of Padova, Department of Surgical and Oncological Sciences Clinica Chirurgica II, Via Giustiniani, 2, 35128 Padova, Italy.

PII: S0093-7754(02)50270-0

doi: 10.1053/sonc.2002.34119

Seminars in Oncology
Volume 29, Issue 4 , Pages 400-409 , August 2002

Article Tools